Quick Answer
PROVECTUS BIOPHARMACEUTICALS, INC. reported Total Revenue of $336.1 thousand for fiscal year 2025.
PROVECTUS BIOPHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $336.1K -45.5% |
$617.1K +10.7% |
$557.7K -43.6% |
$989.0K | — | — |
| Revenue (ASC 606) | $336.1K -45.5% |
$617.1K +10.7% |
$557.7K -43.6% |
$989.0K | — | — |
| Net Income | -$5.43M -14.8% |
-$4.73M -52.6% |
-$3.10M +12.7% |
-$3.55M +35.8% |
-$5.54M +17.0% |
-$6.68M +3.5% |
| Diluted EPS | -$0.01 +0.0% |
-$0.01 +0.0% |
-$0.01 +0.0% |
-$0.01 | — | — |
| Total Assets | $697.5K -30.7% |
$1.01M -30.5% |
$1.45M -28.9% |
$2.04M -42.0% |
$3.51M +496.3% |
$589.2K -60.1% |
| Cash and Equivalents | $251.3K -18.3% |
$307.4K +301.5% |
$76.6K +254.4% |
$21.6K -96.8% |
$683.0K +602.4% |
$97.2K -83.5% |
| Stockholders Equity | -$6.30M -5.7% |
-$5.96M +21.5% |
-$7.59M -21.9% |
-$6.23M -48.7% |
-$4.19M +86.1% |
-$30.21M -25.5% |
| R&D Expense | $1.90M -7.5% |
$2.05M +17.2% |
$1.75M -26.8% |
$2.39M -8.4% |
$2.61M -7.3% |
$2.81M -29.7% |
| Operating Income | -$5.29M -16.8% |
-$4.53M -56.2% |
-$2.90M +15.4% |
-$3.43M +26.6% |
-$4.67M +5.9% |
-$4.96M +21.2% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 420.28M +0.0% |
420.28M +0.2% |
419.52M +0.0% |
419.45M +0.0% |
419.45M +5.2% |
398.81M +2.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2025 | $57.5K | -77.5% | -79.4% |
| Revenue (ASC 606) | June 30, 2025 | $57.5K | -77.5% | -79.4% |
| Net Income | September 30, 2025 | -$1.31M | -29.3% | +27.7% |
| Diluted EPS | September 30, 2025 | $0.00 | — | — |
| Total Assets | September 30, 2025 | $419.9K | -47.6% | -41.9% |
| Cash and Equivalents | September 30, 2025 | $72.5K | -61.3% | -81.2% |
| Stockholders Equity | September 30, 2025 | -$6.15M | -13.4% | -4.8% |
| R&D Expense | September 30, 2025 | $345.9K | -16.5% | -60.1% |
| Operating Income | September 30, 2025 | -$1.28M | -33.5% | +29.2% |
| Shares Outstanding | September 30, 2025 | 420.28M | +0.0% | +0.0% |
- PROVECTUS BIOPHARMACEUTICALS, INC. reported Total Revenue of $336.1 thousand for fiscal year 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -45.5% in Total Revenue compared to the prior fiscal year.
- PROVECTUS BIOPHARMACEUTICALS, INC. reported Revenue (ASC 606) of $336.1 thousand for fiscal year 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -45.5% in Revenue (ASC 606) compared to the prior fiscal year.
- PROVECTUS BIOPHARMACEUTICALS, INC. reported Net Income of -$5.43 million for fiscal year 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -14.8% in Net Income compared to the prior fiscal year.
- PROVECTUS BIOPHARMACEUTICALS, INC. reported Diluted EPS of $0.01 per share (loss) for fiscal year 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed an increase of +0.0% in Diluted EPS compared to the prior fiscal year.
- PROVECTUS BIOPHARMACEUTICALS, INC. reported Total Assets of $697.5 thousand for fiscal year 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -30.7% in Total Assets compared to the prior fiscal year.
- PROVECTUS BIOPHARMACEUTICALS, INC. reported Cash and Equivalents of $251.3 thousand for fiscal year 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -18.3% in Cash and Equivalents compared to the prior fiscal year.
- PROVECTUS BIOPHARMACEUTICALS, INC. reported Stockholders Equity of -$6.30 million for fiscal year 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -5.7% in Stockholders Equity compared to the prior fiscal year.
- PROVECTUS BIOPHARMACEUTICALS, INC. reported R&D Expense of $1.90 million for fiscal year 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -7.5% in R&D Expense compared to the prior fiscal year.
- PROVECTUS BIOPHARMACEUTICALS, INC. reported Operating Income of -$5.29 million for fiscal year 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -16.8% in Operating Income compared to the prior fiscal year.
- PROVECTUS BIOPHARMACEUTICALS, INC. reported Gross Profit of $0.00 for fiscal year 2011.
- PROVECTUS BIOPHARMACEUTICALS, INC. reported Shares Outstanding of 420.28 million shares for fiscal year 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: